Advances in Pipeline of new COPD Treatments
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder of the lungs that affects about 10% of the adult population and is currently the third leading global cause of death.
COPD is the result of multiple, repeated and dynamic gene–environment interactions, starting early in life, that determine the lung function trajectory that a given individual follows over a lifetime.
Therapeutic Opportunities in New COPD Treatments
Increasing understanding of COPD pathogenesis has opened many new opportunities for drug development, including recently approved monoclonal antibodies that reduce inflammatory cytokine signalling by targeting the IL-4α receptor or the eosinophil-activating IL-5.
Drugs Under Clinical Development
Drugs targeting a range of other culprits involved in COPD, including neutrophils, alarmins and kinases, are also in clinical development.
Future Directions in COPD Trials with New COPD Treatments
As the current pipeline of drugs in development for COPD matures, potential areas for novel therapies continue to emerge while lessons from ongoing trials such as patient stratification can be used to refine the design of future trials in this disease.
Authors
Alvar Agusti, Dave Singh, Rosa Faner
Read more details at
Fecha de publicación
Published: 22 September 2025
Categorías asociadas al artículo
Noticias relacionadas
Treatable Trait Guided Asthma Management: A Feasibility Study
Protocolised treatable trait-based asthma management was acceptable to patients not under the care of a severe asthma clinic, associated with significant clinical benefit, and a full trial appears feasible.
Occluding mucous airway plugs in patients with obstructive lung diseases: a new treatable trait?
Airway mucous plugging is associated with exacerbations, lung function decline, and mortality in COPD, asthma, and bronchiectasis. Identifying it as a treatable trait may improve patient outcomes through airway clearance techniques and pharmacological strategies.
Change is in the air: key questions on the ‘Treatable Traits’ model for chronic airway diseases in primary care
Explore Treatable Traits model for chronic airway diseases like asthma and COPD in primary care. Learn about seven key traits — airflow obstruction, eosinophilic inflammation, adherence, inhaler technique, smoking, low BMI/obesity and anxiety and depression — that guide personalized care.
Aging and Metabolic Changes in COPD Patients
Explore the metabolic changes in COPD patients, highlighting the influence of aging and sex, with pronounced effects in males. Discover how COPD affects protein metabolism and energy production, emphasizing early aging’s impact.
Treatable traits in pre-COPD: Time to extend the treatable traits paradigm beyond established disease
Explore how the treatable traits approach can be applied to pre-COPD, potentially preventing full disease development. Learn about GETomics and its role in understanding pre-COPD through gene-environment interactions.
From treatable traits to GETomics in airway disease: moving towards clinical practice
The treatable traits approach represents a strategy for patient management. It is based on the identification of characteristics susceptible to treatments or predictive of treatment response in each individual patient.
Imagen desarrollada IA